Adderall alternatives reddit
I Tried Functional-Mushroom Gummies As a Natural Adderall Alternative
- I tried a "functional-mushroom" supplement containing a fungus used in traditional Chinese medicine.
- Gwella's founder said he began experimenting with mushrooms to create an alternative to Adderall.
- I felt slightly more focused 45 minutes after consuming the functional-mushroom gummy.
Thanks for signing up!
Access your favorite topics in a personalized feed while you're on the go.
As psychedelic mushrooms continue to gain interest from investors and researchers, some companies are experimenting with "functional mushrooms," fungi with properties beyond just nutrition, such as reducing stress or increasing focus.
Gwella, a Toronto-based wellness startup founded in 2020, is one such company. Last year, Gwella launched a gummy derived from ingredients in lion's mane, one of a handful of functional mushrooms used in traditional Chinese medicine along with reishi and turkey tail.
Peter Reitano, the founder of Gwella, said he's been growing functional mushrooms for about a decade. He said Gwella's chief science officer, Daniel Sanders, began experimenting with lion's mane while he was in school to replace Adderall as a "study aid." It gave them the idea to explore the potential of lion's mane as a natural alternative to improve cognition and increase focus, Reitano added.
Adderall is a widely prescribed drug that combines amphetamine and dextroamphetamine, two stimulants, to improve focus for people with attention-deficit hyperactivity disorder, or ADHD. While stimulants seem to be effective for about 70% of patients, Adderall can come with serious risks like addiction and worsening of existing heart conditions.
"We wanted to create a really healthy product that had short-term benefits — i.e., focus, cognition, energy — but also had these long-term compounding benefits with regular use through functional mushrooms like lion's mane," Reitano said in an interview with Insider.
I tried Gwella's gummy product, called Mojo, to see if it would help my focus, and asked an external expert to assess whether they thought the short-lived effects I felt were caused by the lion's mane, other ingredients, or a placebo effect.
Research is limited, but appetite is big for functional mushrooms
Gwella is a newcomer in the growing functional-mushroom industry, which generated $7.98 billion in 2020 and could reach a whopping $19.33 billion by 2030, according to a November report from Allied Market Research.
Other big players include Bella Hadid's new "functional beverage," Kin, a nonalcoholic spritz that uses reishi mushrooms, and Moon Juice, a buzzy Los Angeles-based wellness company that started as a single juice shop in 2012 and now makes $20 million in annual sales on products including powdered chaga mushrooms.
Research on the effects of mushroom-derived supplements like adaptogens are inconclusive, but Chris D'Adamo, an epidemiologist and assistant professor at the University of Maryland School of Medicine who studies wellness and dietary supplements, described lion's mane as the "all-star" of functional mushrooms due to its positive effects in animal studies and some small human studies.
I tried a functional mushroom-infused gummy to help get me focused. Allana Akhtar/InsiderA 2009 study in Japan with 30 elderly participants suggested people who consumed 3 grams of lion's mane extract for 16 weeks performed slightly better on cognitive tests than a placebo group, but the study has not been replicated.
Multiple studies in mice have suggested lion's mane improved short-term memory.
According to D'Adamo, while more research is needed on the effects, the appetite for functional mushrooms is propelled by the long tradition of mushroom use in Chinese medicine. "If you look at mushrooms, in particular, there are a tremendous amount of studies and thousands of years of history on utilizing and capitalizing on the medicinal properties that they have," D'Adamo said in an interview.
Gwella also adds about 90 milligrams of nootropics to the functional-mushroom gummies. Nootropics are substances that potentially improve cognitive functioning and are found in caffeine, tea, and creatine.
Dr. David A. Merrill, a psychiatrist and director of the Pacific Neuroscience Institute's Pacific Brain Health Center at Providence Saint John's Health Center near Los Angeles, previously told Insider nootropics provide the most benefit when a person is already having trouble focusing. Furthermore, Merrill said factors like sleep, stress, diet, and exercise might have greater long-term effects on cognitive functioning,
I took my first Mojo gummy at 1
1:30 a.
m. Gwella's website says Mojo's effects might kick in hours after taking a gummy. Gwella According to Gwella's website, the functional-mushroom gummy takes about one hour to begin having an effect. The company told Insider the timeline comes from its in-house science team, which used third-party research and data from community product testing. The company did not share details of the people and sample size involved in those studies.
On the Mojo label, the company recommends taking half of a gummy to start. Unfortunately, I skimmed the instructions and assumed one gummy was the starting dose.
The taste was bearable, but I wouldn't say I particularly enjoyed it. It was a "wild strawberry and zesty tangerine" flavor, but it left an aftertaste in my mouth for about 15 minutes that felt like an artificial sweetener.
About 45 minutes in, I started to feel relaxed, not shaky or panicky as if I've had too much coffee but still focused and able to work. While I have never taken Adderall, users typically feel "energetic, focused, excited, or self-confident" immediately after taking the pill, according to Medical News Today. I felt only slightly more focused and didn't notice any other changes to my mood or attention.
12:30 p.m.: I felt a bit more focused Mojo is a supplement that uses lion's mane, a "functional mushroom" used in traditional Chinese medicine. Allana Akhtar/InsiderThat slight buzz I felt went away within 10 minutes.
I was left still feeling focused, but I couldn't feel any other sensation. The focused feeling was slight, and I wondered whether it had come from the tea I drank.
When I described my experience taking Mojo to D'Adamo, the epidemiologist said it's "probably likely" Mojo had a subtle effect on my increased focus. People can feel the effects of Red Bull or coffee more intensely than they would feel the effects of lion's mane, D'Adamo added, but he said there is some evidence that extended use of lion's mane can result in increased focus in the long term.
D'Adamo said consumers would need to take at least 3 grams of lion's mane to get the short-term cognitive benefits from the mushroom. Gwella said there is 52.5 milligrams in each gummy, or just 0.05 of a gram — far less than D'Adamo's suggested dose.
At about 10 minutes into the second hour, I felt a slight sensation on my tongue, as if it were going a bit numb. Then I felt the tingling sensation return even stronger, and I felt it in my fingertips.
I would describe the sensation as a dulled-down version of the 15-minute tingling I get from a pre-workout 300-milligram caffeine supplement. Gwella said this is not a common reaction to the gummy, based on the company's research.
I ate around this time to see how that would affect my experience. Usually after lunch, I feel fatigued and am in a slump and need at least 30 minutes to get productive again, but today I was able to get to work right away after I ate. I'm not sure whether it's because of the mushrooms or if I got good sleep the night before, but D'Adamo said while sleep is an important factor in cognition, the lion's mane could have had a subtle effect on my improved focus.
Whatever effects I felt I had were over by now, so I took two more just to see what would happen. Gwella recommends taking between a half gummy to two when dosing because users will react to the mushroom differently.
I was pleasantly surprised at my focus in the hour after I had my first gummy but disappointed that the effects seem to have dissipated rather quickly. I hoped that by taking two I would feel the effects longer and stronger.
I felt the same effects taking two Mojo gummies compared with one: I felt slightly more focused 45 minutes after consuming the supplement, but the feeling went away within an hour after that.
Overall, I would say I enjoyed my experience taking the Mojo gummy and would use it again if I had a big deadline coming up as an alternative to a cup of coffee.
FDA confirms shortage of Adderall, with delays possible until end of year
The Food and Drug Administration on Wednesday confirmed a nationwide shortage of the attention-deficit/hyperactivity disorder medication Adderall, more than two months after some pharmacies reported difficulties filling prescriptions.
The shortage affects the immediate-release form of Adderall, a stimulant that helps manage ADHD symptoms.
The FDA said in a statement that it was in “frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays.”
Teva Pharmaceuticals is the country’s largest manufacturer of Adderall. It first reported delays in filling orders in August, attributing them to a labor shortage on its packaging line that it said had since been resolved.
Spokesperson Kelley Dougherty said Thursday that Teva expects “inventory recovery in the coming months.”
“Teva has active supply of both branded Adderall and its generic version and continues to produce and refill the channel regularly at levels above historical demand. It is possible that some people may encounter a backorder (intermittently) based on timing and demand, but these are only temporary,” she said in a statement.
Dougherty added that Teva expects “intermittent delays through end of year.”
The supply from the other Adderall manufacturers isn’t enough to meet the need, the FDA said.
The FDA suggested that “patients should work with their health care professionals to determine their best treatment option,” which may include alternatives like the drug’s extended-release formulation.
The shortage has been “a mess” for people who take ADHD stimulants, said Dr. Gabrielle Shapiro, a psychiatrist and a professor at the Icahn School of Medicine at Mount Sinai in New York.
Shapiro, who sees patients of all ages, said the challenge is particularly acute for children who have been off their medication as the new school year has started.
“Parents are panicked. Their children are being sent home from school or told they cannot come back if they are not on their meds,” said Shapiro, who is also a member of the American Psychiatric Association’s council on children, adolescents and their families.
“I have high school students that are trying to take their SATs and do their applications for college, and they can’t focus. They can’t get them done.”
“I have high school students that are trying to take their SATs and do their applications for college, and they can’t focus. They can’t get them done.”
Psychiatrist Dr. Gabrielle Shapiro
Adderall is a controlled substance regulated by the federal Drug Enforcement Administration. Dougherty said Teva is “working closely with our manufacturing facility and the DEA to see what additional volume we may be able to support in the future.”
Emily Hoffman, 34, of Seattle, said she has ping-ponged between pharmacies trying to find one with Adderall in stock. Recently, she said, she had to go a week without her medication.
“The fact that it’s controlled means you can’t ask for the prescription early," she said. "I have to call when I’m down to my last pill or two.”
At Parker’s Pharmacy in Baton Rouge, Louisiana, sales director Tylan Jones said that he has been able to fill Adderall prescriptions for current patients but that there have been delays.
He has had to turn away patients from other pharmacies because there isn’t enough supply for both current and new customers, and pharmacies are subject to limits on how much of a controlled substance they can distribute.
“We don’t want to neglect our patients that we’re currently filling here, so, unfortunately, we have to send some patients on their way,” Jones said.
“Patients sometimes get very frustrated, aggravated, sometimes even aggressive,” he said. “But I would say usually it’s just patients are disappointed and anxious.”
While Adderall has been in short supply before — the FDA reported a shortage from September 2019 through this May — Jones said this shortage has been unusually difficult.
“It is something we’ve seen before, but not to the severity, this bad, before,” he said.
The shortage has hit pharmacies differently
Some pharmacies have been having trouble filling Adderall prescriptions since the summer. A survey by the National Community Pharmacists Association conducted from July 25 through Aug.
5 found that roughly 64% of about 360 independent pharmacies that responded were having difficulty obtaining Adderall.
Large pharmacy chains CVS and Walgreens told NBC News in late August that they weren’t experiencing widespread problems, although many people who had unsuccessfully tried to fill their prescriptions at those pharmacies voiced frustration on social media at the time.
CVS said Thursday it was “aware of intermittent shortages of generic amphetamine medication in the supply chain.”
As for the patients who say the shortages have stretched as far back as August, CVS Health spokesperson Matt Blanchette said only, “We are working with our patients to meet their needs.”
Walgreens didn’t answer questions about its current Adderall supply other than to reiterate that the FDA had confirmed a nationwide shortage.
“Questions about supply and availability need to be directed to manufacturers,” it said.
A crucial tool in managing ADHD
ADHD is a neurodevelopmental condition marked by inattentiveness, impulsivity and/or hyperactivity that is severe enough to interfere with school, work and other aspects of life.
The Centers for Disease Control and Prevention estimates, based on data from 2016 to 2019, that about 10% of children are diagnosed with it, with boys more likely to receive diagnoses.
Adderall and other stimulant drugs are commonly used to manage ADHD, and demand is higher than ever: Adderall prescriptions dispensed in the U.S. spiked to 41.4 million last year, up by 10.4% from 2020, according to IQVIA, an analytics provider for the life sciences industry. Experts say more awareness about ADHD has contributed to the increase, although there is also concern that stimulants have been overprescribed, because the drug can be abused if it’s taken improperly or without a prescription.
In May, Walmart and CVS announced they would stop filling prescriptions for controlled substances from telehealth startups such as Cerebral and Done Health, which prescribe stimulants and gained footing during the pandemic.
For those who need it, Shapiro said, going without ADHD medication can be disastrous.
“They’ll feel badly about themselves,” she said. “You have a kid that was doing well in school, doing their homework, and all of a sudden they’re bouncing off the wall.”
Fasoracetam. Fasoracetam (Fasoracetam) is… | by Braint
Fasoracetam (Fasoracetam) is an exotic nootropic from the racetam family that has been shown to reduce anxiety, relieve symptoms of depression, and improve memory and cognition. Apparently, tolerance does not develop to the action of the drug and it does not cause dependence.
Summary:
The newly discovered fasoracetam is a powerful and promising nootropic in the racetam family. It can help improve mood and stabilize the emotional background, improve memory and activate cognitive abilities, and also relieve symptoms of depression and anxiety. This drug could be used to relieve the symptoms of ADHD without the use of psychostimulants. Although much remains to be learned about the drug, users provide evidence that this nootropic has a unique effect and high efficiency, in particular, it enhances cognitive abilities without leading to a decrease in effect (tolerance) or addiction over time.
Although fasoracetam is relatively new among nootropics, it was developed over 20 years ago by the Japanese pharmaceutical company Nippon Shinyaku as a possible treatment for vascular dementia. Work with the drug was stopped after unsatisfactory results of clinical trials, but in 2013 the data obtained from the study of the drug were acquired by the American company NeuroFix (now a subsidiary of Aevi Genomic Medicine).
Fasoracetam's clinical trials were relaunched in 2016, this time focusing on the drug's use in the treatment of attention deficit hyperactivity disorder (ADHD) in children, which has a specific mutation in the glutamate receptor system. The trials, which have already reached the third stage, show great promise for the drug as an alternative to the psychostimulant Adderall and other amphetamine derivatives for the treatment of ADHD.
Fasoracetam has not been approved by the FDA and is not currently regulated in any way. However, in 2016, the FDA accepted a new Fasoracetam Investigational New Drug Application for review, and a second round of research is reportedly planned for 2018.
[1]
Whether or not fasoracetam is approved as a treatment for ADHD, with similar mechanisms of action, it could be used as a powerful nootropic.
Improves memory and learning:
Animal tests show that fasoracetam is effective in reducing memory impairment, minimizing forgetfulness and amnesia symptoms. [2] Although there are no human studies, many users report significant improvements in memory with the drug. [3] [4] This statement is supported by the neurochemical aspects of how the drug works; Like other nootropics in the racetam family, fasoracetam increases the concentration of acetylcholine in the brain, the main neurotransmitter responsible for memory, learning, and cognition.
Reduces symptoms of depression and anxiety:
Fasoracetam improves mood, reduces anxiety and relieves symptoms of depression by acting on the two most important emotional neurotransmitters, glutamate and gamma-aminobutyric acid (GABA).
By influencing the levels of GABA, which is the main neurotransmitter responsible for inhibition processes, and suppressing the excess production of glutamate, an excitatory neurotransmitter, some users describe the effect of fasoracetam as a smooth and gentle improvement in mood, a feeling of relaxation and calmness.
There are no publicly available studies on the effects of fasoractam on mood, anxiety, or depression in humans, but many users report feeling calm, reduced anxiety, and some reduction in depressive symptoms when taking the drug. [5] Animal testing also confirms these effects, showing that animals treated with fasoracetam in stressful situations were less prone to panic, stupor, and other conditions that occur with stress, anxiety, and depression. [6]
Potential treatment option for ADHD:
The only published human study of fasoracetam showed that this drug could be a powerful treatment for ADHD [7]. The study involved 30 patients aged 12 to 17 years.
The effectiveness of fasoracetam in the treatment of ADHD in adolescents was tested, in which a specific mutation was found in a group of genes responsible for glutamate receptors. It is very likely that this mutation is associated with ADHD, and it is present in a significant percentage of adolescents with this diagnosis.
Patients who took fasoracetam during the five weeks of the study had a significant improvement in all clinical parameters during the study, and improvement in ADHD symptoms was recorded during testing after discontinuation of the drug.
The drug increases creativity and motivation:
As more people take the drug and describe its effect, there is peculiar evidence of its ability to activate creativity in thinking and increase motivation for mental work. Many users of the drug report that it not only makes them feel more inspired, but also motivates them to start, tackle, and successfully complete creative tasks.
Although the data from users are not supported by data from clinical studies, the reliability of these reports deserves attention, and the ability of fasoracetam to increase creativity should be taken into account, which may be related to the ability of the drug to activate the synthesis and release of the neurotransmitter acetylcholine, which largely corresponds to for learning processes and cognitive skills.
Drug reduces social anxiety:
Many users of fasoracetam report a marked reduction in social anxiety, an effect that users have found to be similar to that of phenibut. Users reported less lethargy and less intensity of DRDP symptoms, increased ability for social interaction, greater confidence, and the ability to construct sentences more easily in dialogue. Although there are no clinical studies to confirm these data, this effect should be expected logically, given the actions of fasoracetam on the synthesis of GABA and its increase in its level, changes in the concentration of glutamate and other neurotransmitters.
Fasoracetam's exact mechanisms of action are not well understood, but it is thought to work by affecting the synthesis and release of glutamate, GABA, and acetylcholine, three of the brain's most important neurotransmitters responsible for intelligence.
Regulatory action on the glutamatergic system:
Fasoracetam is known to modulate some of the brain's glutamate receptors, an essential activating neurotransmitter required for all aspects of brain function.
Glutamate abnormalities have been associated with various physical and psychiatric disorders, including major depressive disorder, ADHD, schizophrenia, epilepsy, and neurodegenerative diseases such as Alzheimer's disease.
Fasoracetam is active on a specific group of glutamate receptors called metabotropic glutamate receptors, or mGluRs, which have many functions in the body and brain but are primarily involved in learning, memory and anxiety. Eight known mGluRs work together to gently maintain neurotransmitter balance, with two increasing neuronal firing and the other six reducing the risk of neurotoxicity by reducing neuronal firing as needed.
In animal studies, fasoracetam successfully restored the function of two damaged mGluRs, thereby slightly reducing glutamate activity in the brain [8]. It is believed that fasoracetam can modulate all metabotropic glutamate receptors, restoring the balance of the glutamatergic system as a whole. This may explain why fasoracetam may be effective for ADHD, as this syndrome is usually associated with low levels of glutamate without having the stimulant effects of amphetamines.
GABA regulation:
Glutamate is also a precursor to GABA, an important inhibitory neurotransmitter that is also associated with learning but has a sedative, calming effect, helps reduce anxiety and promotes sleep. Studies have shown that fasoracetam increases the activity of GABA-B receptors, making more GABA available to this type of receptor in the brain and central nervous system.
This action, especially in combination with glutamate receptor modulation, underlies fasoracetam's ability to alleviate depression, reduce anxiety, relieve symptoms of social phobia, and increase motivation. In studies on rats, these effects were considered as an opportunity for the treatment of artificially induced depression and states of psychogenic stupor [9].
Increased availability of acetylcholine:
Fasoracetam is a potent cholinergic agent, significantly increasing choline uptake in the cerebral cortex and hippocampus. The brain uses the extra choline to make more acetylcholine, a neurotransmitter currently theorized to be responsible for learning, memory, and other cognitive skills.
This cholinergic action, characteristic of piracetam, aniracetam and other nootropics from the racetam family, can significantly enhance almost all cognitive functions. However, it can also lead to a rapid depletion of the choline store in the brain, which can lead to headaches, clouding of consciousness and lower mood. This side effect can be largely prevented by taking choline precursors along with racetam family nootropics.
The effects of fasoracetam have been little studied in humans and dosing recommendations do not currently exist. In clinical trials of fasoracetam as a treatment for ADHD, adolescents received the drug orally at doses ranging from 100 mg to 400 mg twice daily. However, fasoracetam is a very potent compound, with twice-daily doses of 20 to 60 mg reported by users. As with other nootropics, it is optimal and safe to start with the lowest effective dose and gradually increase it until the desired effect is achieved.
Some users report that sublingual use is more effective, but others find that the extremely unpleasant taste makes this method extremely difficult to take.
One of the most interesting aspects of the action of fasoracetam was revealed in clinical trials in patients with ADHD: During the five weeks of the test, tolerance and addiction to the action of the drug did not occur, on the contrary, the maximum effect was observed during the last week of the study. In addition, neither studies in patients with ADHD nor previous animal studies indicate the possibility of addiction. While this is reassuring, it does not mean that tolerance and addiction development to fasoracetam is not possible, so users are strongly advised to keep in mind that the drug is not yet well understood and it may be safer to use it in short courses rather than all the time.
Fasoracetam is eliminated from the body through the kidneys, so older people or people with impaired kidney function should consult a doctor before taking fasoracetam. Pregnant or breastfeeding women should not take fasoracetam as its effects and mechanisms of action on the fetus are unknown.
Fasoracetam appears to be safe and well tolerated when taken by healthy adults. The most common side effects are the same as with the rest of the racetam family of drugs: temporary fatigue, digestive disorders and headaches.
There is no information on specific interactions between fasoracetam and other drugs, but users who have any health problems or are taking any potent drugs should consult a doctor before starting fasoracetam.
Fasoracetam & Choline Precursors Stack:
Fasoracetam can be taken alone, but like other racetams, it usually works well with additional choline sources for optimal results.
Example stack:
Fasoracetam 20mg 1-2 times a day.
300 mg citicoline 1-2 times a day.
Fasoracetam is a new, experimental drug, but it is already quite popular among people taking nootropics.
Many consider the drug to be good for reducing anxiety, treating depression and restoring motivation, while others report the ability of the drug to increase clarity of thinking, learning ability and focus on solving intellectual problems.
The drug is considered safe and well tolerated when taken responsibly. At the moment, there is no evidence that taking fasoracetam leads to the development of tolerance or dependence.
If you're looking for a nootropic that can help with anxiety and depression, increase focus, and increase cognition without disturbing your sleep or making you jittery, Fasoracetam might be the remedy you're looking for.
[1] - http://adisinsight.springer.com/trials/700282695
[2] - https://www.ncbi.nlm.nih.gov/pubmed/10494996
[3] - https:/ /www.reddit.com/r/Nootropics/comments/56cuxi/oh_my_fasoracetam_is_effective/
[4] - https://www.reddit.com/r/Nootropics/comments/70pzza/fasoracetam_has_changed_my_life/
[5] - https ://www.reddit.com/r/Nootropics/comments/4g6vr8/fasoracetam_my_experience/
[6] - https://www.ncbi.nlm.nih.gov/pubmed/9424016
[7] - https: //www.ncbi.nlm.nih.gov/pubmed/29339723
[8] - https://www.ncbi.nlm.nih.
gov/pubmed/9134967
[9] - https://www.ncbi.nlm.nih.gov/pubmed/9424016
V Turkey is better to rest than to play. Direct speech
Main » Open area » Direct speech
May 05, 2012
The Russian national ice hockey team started its first game at the World Championship against Latvia a little earlier than the women's volleyball team had its semi-finals of the Olympic qualification in Ankara. Most of the spectators, those who stayed at home these days, and did not go to the country, watched both games at the same time. The male half of the fans for sure. Here I have, both the TV and the computer are turned on, where they show hockey and volleyball, respectively. As for hockey, goals are usually repeated, so focusing on volleyball, we begin to worry about our girls, besides, the semi-final is no joke.
The Sports Palace in Ankara resembles a beehive, it buzzes so unanimously. Only the bees in it are all red, the fans are dressed in the color of the national flag of Turkey.
We start the first game, as has already become a tradition at this tournament, slightly inferior to our rivals. It would be nice if they outplayed us, while, unfortunately, we make mistakes ourselves more often. One of the episodes was so out of the ordinary, even I rarely saw the ball that flew off after our attack from the block of rivals, along a fairly gentle trajectory, fell exactly in the middle of the court, despite the fact that none of the players made an attempt to bring it to new attack. But the Turkish women got excited, and we skillfully took advantage of this. Startseva gives the "fast" to Borodakova, who knocks him past the block diagonally. On the first technical we go ahead by a point. I note that ours defend well, the first excitement has passed, and we obviously attack more often than our rivals. Sokolova and Perepelkina increase our lead 12-9, but Gamova in a difficult situation hits a little wider than the site. Then we skip ace. Although, while Gamova is on the block, they are very afraid of us.
Gumyush first hits out, but on her second attack she didn’t figure out what to do - she just pushed the ball into Ekaterina’s hands. Gamova scores the 16th point, the gap becomes the largest in the game 16-12.
During the timeout, the red bees begin to sing loudly in unison, trying to inspire their team. After a mistake in the attack, Koshelev is replaced by Obmochaev. Natasha did not immediately get a reception, and even Gamova was blocked from the back line, then the Turkish women themselves scored the final game, the score becomes equal, 18 each. They have a double shift at this time. So far, everything is smooth, both teams keep eating, the Turkish women have Ozsoy, and we have Gamova coming back forward. My heart sank when Startseva missed Sokolova's pass to her favorite "return", but she was lucky, the opponents attacked the passing one. Obmochaev "wets" the Turks in the attack, but does not manage to break away, if not for Darnel's mistake. We have the first set-ball, Gamova hits, it seems, exactly, but the judges did not think so.
For the riot, a warning to Ovchinnikov from the chief. How the wingers played out on both sides! And as soon as Aydemir tried to give a pass to the center, shyness immediately arose, which ours seized on. The hardest set, but it's ours, 28-26!
In the second game, the game of the Turkish team was still reduced to extreme forwards, well, where are they against ours?! Perepelkina broke up with us, but Borodakova was not inferior to her. Obmochaeva also, apparently, had sat too long on the bench, so she demonstrated her skills with ease and grace. It seems that Ovchinnikov did not act according to the principle “there is one girl there”, with rare exceptions, the Turkish women attacked against our single block, everyone, not only that girl. Fake attacks have also been neutralized. From time to time, the opponents' serve interfered with us, but the Turkish women clearly did not differ in stability today. It seems that they want to equalize the score, but either they hit the net, or they won’t be able to hit.
Only with a score of 22-22 did they succeed, which immediately caused a timeout for Ovchinnikov. And here the Turkish libero begins to work wonders, first, with her support, the Turkish women win back a set-ball, and then she scores two hardest replays against Gamova. Our defenders were not there, and so they "lulled" our vigilance. As they say, everything is just beginning! 1-1.
In the third installment, the hosts equalized the score much faster and even seized the initiative, right before the first technical one. Motta set up his wards in a fatherly way, glasses give him even more solidity. And our girls did not even think of giving up, because at stake (everyone is already saying, well, how will they not get tired?) An Olympic ticket. Neslihan Darnel uses her serve very wisely, until the middle of the game, when the moment allows, she serves in a jump, we have studied this serve well, but it is not always possible to cope with it. And now: ace, they caught Obmochaeva with a block twice, they go ahead by three points.
Ovchinnikov reacts by changing Natalia to Evgenia Estes. Now this is very important, Zhenya can stabilize the reception, then Startseva will have more options for organizing an attack. But while we are losing 12-18... The reception doesn't work either, Erdem's serve is really crazy. I experienced it myself, playing against Fenerbahce. For now, Startseva herself dares to get a discount, but then she immediately receives it from Darnell. We strayed into a simple game, Startseva is forced to run around the entire three-meter zone, fishing for balls. The transmission immediately stopped flying, the attackers are cautious because of the inconvenience. Gamova has become harder to breathe, but does not stop proving her case to the linesman. Reception at Estes also did not work out, the last ball in the set of the Turkish women earned by winning the challenge after her reception. Yes, how can we not now draw an analogy with the statement of the coach of the Dynamo Moscow hockey club Oleg Znarok, who said when his team lost to Avangard Omsk 1-3 in matches in the final series of the Gagarin Cup: “For us, the playoffs are only starts!" If only for our teams the gap in sets 1-2 would become such an incentive to win!
But we start 0-3, Ovchinnikov has to use his first break right away.
Obmochaeva came out at the base. We begin to slowly catch up, but the second referee fixes the net. A couple of good moves by Startseva, we're getting close, 7-8. And then Ozsoy hits out, causing Motta to raise his voice at halftime. Sonsirma was worried about her knee, Ozsoy began to hold on to her shoulder, wrinkling her forehead, but this does not prevent the team from taking two points. Luckily, we're recovering right now. Here comes Merkulova instead of Perepelkina. Obmochaeva hits the Turkish block, the rebound seems to be out, but not in Ankara. Gamova rushes to help Borodakova and blocks Erdem. We are close, 15-16. But after the next attacks of the Turkish women, Ovchinnikov has to defend himself twice, the balls bounce off the block to him. It is a pity that the protection of the coach by the judge is not taken into account. For Ozsoy, any barriers seem to have ceased to exist, but Obmochaeva and Borodakov are again blocked. Then Maria gets out of anger out of anger. The score becomes threatening, 22-16, after which Startseva also throws into the block.
